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Abstract
Background: Mortality of HIV-infected patients initiating antiretroviral therapy in the developing
world is very high immediately after the start of ART therapy and drops sharply thereafter. It is
necessary to use models of survival time that reflect this change.
Methods: In this endeavor, parametric models with changepoints such as Weibull models can be
useful in order to explicitly model the underlying failure process, even in the case where abrupt
changes in the mortality rate are present. Estimation of the temporal location of possible mortality
changepoints has important implications on the effective management of these patients. We briefly
describe these models and apply them to the case of estimating survival among HIV-infected
patients who are initiating antiretroviral therapy in a care and treatment programme in sub-Saharan
Africa.
Results: As a first reported data-driven estimate of the existence and location of early mortality
changepoints after antiretroviral therapy initiation, we show that there is an early change in risk of
death at three months, followed by an intermediate risk period lasting up to 10 months after
therapy.
Conclusion: By explicitly modelling the underlying abrupt changes in mortality risk after initiation
of antiretroviral therapy we are able to estimate their number and location in a rigorous, data-
driven manner. The existence of a high early risk of death after initiation of antiretroviral therapy
and the determination of its duration has direct implications for the optimal management of
patients initiating therapy in this setting.
Background
In a clinical trial, 1120 HIV-infected individuals initiated
antiretroviral therapy (ART) in rural Uganda. One hun-
dred and five subjects died during the study. Table 1
shows the number of patients dying per 100 person-years
of follow up in every period post ART initiation. Inspec-
tion of the mortality rates in Table 1 suggests that the risk
of mortality (hazard) immediately after ART initiation is
higher than the hazard in later periods. The possibility
that there is a point in time that the hazard of death
changes abruptly, from an early high level to a lower level,
has broad implications for the management of these
patients. A number of reports have indicated that mortal-
ity risk is higher immediately following the start of ther-
apy [1-3]. These reports consider that the period of high
mortality lasts about three to six months after start of ther-
apy. To analyze this type of survival data, acknowledge-
ment of the possibility of a sharp decline in the hazard of
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death is essential both for the analysis itself, and in a data-
driven manner, for the probable location of the change-
point of mortality risk. In the problem discussed here, it is
useful to derive objective data-driven estimates of the
number and temporal location of these risk changepoints,
since their existence has broad implications on clinical
protocols developed for the management of these
patients. The class of Weibull models with changepoints is
suitable for this purpose as these models explicitly model
the underlying hazard of mortality and, therefore, are use-
ful in better understanding the disease process.
Methods
The Weibull model of patient survival
A frequently used mathematical model of patient survival
is based on the Weibull probability distribution function
for survival time T. The baseline hazard of this model for
the ith subject is
Covariates are incorporated straightforwardly so that h(ti;
z) = h0(ti)eβ'z, i.e.,
where β and z are the vectors of coefficients and covariate
values respectively. The cumulative hazard of the Weibull
model from the time origin up to time ti is
so that
This is a proportional hazards model in the sense that the
hazard at time ti, given the covariates z, is h(t; z) = ho(t)ϕ
where ϕ = eβ'z is a proportionality constant that is not
dependent on time. The log cumulative hazard is also lin-
ear in both time and the covariates, i.e., log H(ti; z) = ρlog
ti - ρlog λ + β'z or, in the notation of Royston and Parmar
[4],
where s(x; γ) = γ0 + γ1x with γ0 = -ρlog λ, γ1 = ρ and x = log
ti. The Weibull model is a generalization of the common
exponential survival model (having ρ = 1). It is more flex-
ible for many real-world situations as, in contrast to the
exponential model, it does not assume constant hazard of
death.
Extensions of the Weibull model
As flexible as the Weibull model may be, it may not ade-
quately reflect changes in the hazard over time such as in
the case of very high mortality hazard early after the start
of ART. We consider one such extension, which includes
Weibull models with changepoints.
Weibull model with changepoints
The general m-changepoint model for the Weibull is given
by Noura and Read [5]. They consider the baseline log
cumulative hazard for the ith subject
where
are changepoint indicators. Ensuring that the piece-wise
log-cumulative hazards (and thus the piece-wise survival
curves) meet at the changepoints aj, for j = 0,,m + 1 (with
a0 = 0 and am+1 = ∞) puts restrictions on the λj parameters
of the m piece-wise Weibull distributions making up the
model. Details can be found in the Noura and Reed [5]
analysis. The usual logarithm of the survival likelihood
(i.e., the probability that the death and censoring times
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Table 1: Death rate (per 100 person-years) after initiation of ART
Time period
< 3 months 3–6 months 6–12 months 12–18 months 18–24 months
Subjects at interval start 1,120 1,074 1,036 994 959
Deaths 45 15 23 13 6
Patients lost 1 23 19 22 20
Person years 273.8 266.2 508.7 491.6 474.7
Death rate 16.4 5.6 4.5 2.7 1.3Journal of the International AIDS Society 2009, 12:9 http://www.jiasociety.org/content/12/1/9
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will be as observed in the data), obtained from the piece-
wise Weibull model is
where δi is a censoring indicator and
In the simplest case of a single changepoint a, we will have
two Weibull models, before and after the changepoint,
with scale and shape parameters (λ1,  ρ1) and (λ2,  ρ2)
respectively. For a given single changepoint a, the log like-
lihood is, by (2)
The log cumulative hazard log H(ti) is obtained by adapt-
ing equation (3) for the case of a single changepoint.
Doing so we obtain the log cumulative hazard for the sin-
gle changepoint model
where the changepoint indicators in (3) are, in the case of
two changepoints, c1i = ci and c2i = (1 - ci). The likelihood
in (4) is called the log profile likelihood associated with a
particular choice of changepoint a. The analysis proceeds
by maximizing (4), with respect to ρ1, ρ2 and λ1, for given
candidate values of the changepoint a. Repeating this
process over a number of candidate changepoints and
maximizing the log profile likelihood for each one, we
can determine the optimal changepoint a and the maxi-
mum profile likelihood estimates of the piece-wise
Weibull distributions   and   with
 log a. For more details on the single-
changepoint Weibull model, see [6].
In the case of the Weibull model with two changepoints
a1 and a2, the log profile likelihood is
where
is the log cumulative hazard, and δi, ci1, ci2 and ci3 = 1 - ci1
- ci2 are, respectively, the censoring and changepoint indi-
cators. This profile likelihood can be maximized with
respect to ρ1,  ρ2,  ρ3 and  λ1, over a grid of candidate
changepoint values a1 and a2 until the maximum profile
likelihood is found. This results in the determination of
the optimal changepoints a1 and a2 as well as the maxi-
mum profile likelihood estimates of the three piece-wise
Weibull distributions,  ,   and 
where   log  a1 and 
log a2 [5].
Inference on the changepoints
The location of the changepoint produced by the methods
just outlined does not account for the variability associ-
ated with the estimation procedure. A way to produce
confidence intervals (in the case of a single changepoint)
or confidence regions (in multiple dimensions) is by
inverting the likelihood ratio test [7,8]. That is, the confi-
dence region is comprised of all changepoints a satisfying
where m is the number of changepoints,   is the 1 -
α percentile of the chi-square distribution with m degrees
of freedom, L(a) is the maximized log-likelihood function
evaluated at changepoint a and L(â) is the maximized log-
likelihood function evaluated at the optimal changepoint.
The authors of the aforementioned references contend
that these confidence intervals will perform well even if
the underlying likelihood is not normal.
Incorporating covariates
As shown earlier, factors that are thought to be associated
with the mortality hazard are straightforwardly incorpo-
rated into the model. Estimation of the regression coeffi-
cient  β, associated with one or more factors, proceeds
through maximizing the likelihood equation in (4) or (5),
depending on the model selected. β  is an additional
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parameter for maximization. The estimate of β that maxi-
mizes the profile likelihood, at the optimal value of the
changepoint is the maximum likelihood estimator   (see
[8] for example). As usual, the hazard ratio is equal to eβ.
Variance estimates for  , produced by the inversion of
the information matrix associated with the profile likeli-
hood, are generally not adequate, since they do not reflect
the uncertainty introduced by estimating the change-
points. The conditional variance formula can be used in
this case [8], i.e.,
The first term on the right of equation (6) is the average of
the variance of   and the second is the variance of the
average estimate of  . Both the estimate of each   and
its variance are readily produced in the output of most sta-
tistical software packages used to implement the analysis
Model comparison
Selecting the optimum model among those with the same
number of changepoints can be accomplished, by per-
forming a grid search and evaluating the profile likeli-
hood at a number of candidate changepoints and
selecting the one that maximizes the likelihood.
Selecting the optimal model among models with different
numbers of changepoints can be accomplished by com-
paring the Akaike or Bayesian Information Criterion
(abbreviated as AIC and BIC respectively). Both of these
include a penalty against over parametrization of the
model. Thus, in both cases, the model with the lowest AIC
or BIC is preferred. The AIC criterion is given by the rela-
tionship AIC = 2m - 2 log(L), where m is the dimension of
the model and -2 log(L) is minus 2 times the logarithm of
the maximized likelihood at model convergence (also
called the deviance because it is a measure of the deviation
of the model from the data). The AIC is distributed
according to a chi-square distribution for large samples.
The BIC criterion is similar to the AIC in that it penalizes
models with larger number of changepoints. The BIC is
given by the general equation BIC = m log(n) - 2 log(L),
where n is the number of observations in the model. This
may not be correct in the special case of survival analysis
where subjects provide varying amounts of data depend-
ing on whether they have been observed to die or they are
censored as of the end of the study. We will follow the rec-
ommendation of Volinsky and Raftery [9] and substitute
d, the number of deaths, for n, in the equation for the BIC.
It should be noted that, by the definition of the AIC and
the BIC, among models with the same dimension, the one
maximizing the likelihood is the optimum model with
respect to both the AIC and BIC.
All analyses involving Weibull models with changepoints
were performed using the ml command in Stata version
9.2 (Stata Corporation, College Station, TX). The author
will make the programme code available upon request.
Results
The Home-based AIDS Care Programme
The Home-Based AIDS Care Programme (HBAC) [10] is a
clinical trial examining three different monitoring strate-
gies for HIV-infected patients receiving ART in rural
Uganda. Aggregated data with no information on any of
the three monitoring strategies were used for this analysis.
The HBAC study was approved by the Science and Ethics
Committee of the Uganda Virus Research Institute, the
Institutional Review Boards of the Centers for Disease
Control and Prevention and the University of California,
San Francisco. In total, 1120 HIV-infected patients were
administered antiretroviral medications as part of the
study. The duration of follow-up in this patient cohort
was as short as 10 days and as long as almost 33 months
(median 26.9 months, inter-quartile range 23.9–29.9
months). One hundred and five subjects (cumulative
mortality 9.38%) died in the study after initiation of ART.
Mortality rates over various periods of the study are sum-
marized in Table 1. Over the first two years of follow-up,
95 patients discontinued from the study (cumulative two-
year dropout probability 7.6%). Because of the very low
number of patients who were lost to follow-up during the
study, these data are particularly useful as an illustration
of these methods because they are not burdened by possi-
ble biases resulting from differential vital status assess-
ment of the subjects in the research cohort. This is a
serious problem with cohorts in the same context [11].
Weibull analysis of the Uganda mortality data
A Weibull analysis of the study data is compared to the
Kaplan-Meier estimate of patient survival in Figure 1. It is
clear from the figure, that the Weibull model underesti-
mates patient mortality immediately following ART initi-
ation. For this reason it would be useful to consider more
flexible models that take into consideration possible
changes in hazard over various periods after initiation of
therapy. In addition, detection of times where the risk of
death changes sharply (changepoints), has broad implica-
tions for the management of these patients.
Reanalysis of the data by Weibull models with 
changepoints
The data can be re-analyzed by using more flexible
Weibull models with one or more changepoints.
ˆ β
ˆ β
var( ) var[ |( , )] var [ |( , )] ββ β = {} + {} Ea a E a a 12 12
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Weibull analysis with a single changepoint
To carry out this analysis, we maximize the log profile
likelihood shown in equation (4) for a number of candi-
date early changepoints a. We considered, as candidate
points, any month within the first year after initiation of
ART. This was a deliberate choice since a single change-
point after the first year would be of limited utility for care
purveyors.
The log profile likelihood has a maximum at a = 3. This
means that the model with a changepoint in survival three
months after initiation of antiretroviral therapy (95%
confidence interval 2.1–4.3 months), is the best single-
changepoint model. The estimated Weibull survival is
shown in Figure 2 along with the Kaplan-Meier reference
survival estimate (left panel).
The impression is that the fit, particularly in the period
after the first three months, is particularly good, but the
survival estimate still underestimates the mortality rate in
the later period after initiation of ART. Another informa-
tive figure of the implication of the changepoint model is
the hazard plot shown in the right panel of the Figure 2.
This single-changepoint model reflects a situation of a
very high hazard of death in the first three months after
ART initiation, followed by a period of lower hazard. It is
also worth noting that the construction of the model
ensures that the individual cumulative hazard curves, and
thus the survival curves before and after the changepoint,
will meet resulting in a continuous survival curve. This,
however, is not the case with the hazard curves that are
discontinuous at the changepoint as a byproduct of the
model construction.
Weibull analysis with two changepoints
To address the poor fit in the middle part of the follow-up
period, we add one more changepoint to the Weibull
model. To fit the two-changepoint model, we must maxi-
mize the profile likelihood from equation (5) presented
in the Methods section, for given candidate changepoints
a1 and a2 searching through various combinations of can-
didate changepoints. We considered, as candidate points,
any month within the 18 months after initiation of ART
for both the first and second changepoint.
Performing this analysis, the optimal two changepoints
were found to be at a1 = 3 and a2 = 10 months after initia-
tion of ART.
Kaplan Meier (step function) versus Weibull estimates of  patient survival (smooth curve) Figure 1
Kaplan Meier (step function) versus Weibull esti-
mates of patient survival (smooth curve). Two alterna-
tive analyses of the HBAC survival data
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Survival estimates produced by Kaplan Meier versus a Weibull model with one changepoint (left panel) and hazard plot of the  Weibull single-changepoint model (right panel) Figure 2
Survival estimates produced by Kaplan Meier versus a Weibull model with one changepoint (left panel) and 
hazard plot of the Weibull single-changepoint model (right panel). These are the estimates of the survival produced 
by the Weibull model with one changepoint (left panel). This panel is like the one on Figure 1 but with a "kink" in the Weibull 
curve. The hazard plot of the Weibull single-changepoint model is also given (right panel).
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The new survival estimate is shown in Figure 3 (left
panel). The fit from the two-changepoint Weibull model
is very good throughout the post-ART period. A hazard
plot of the two-changepoint problem is shown in the right
panel of Figure 3. The hazard plot implies that there are
three periods after initiation of ART. The first is the initial
period of high risk immediately after initiation of ART
that extends up to three months from start of therapy, fol-
lowed by the second, an intermediate risk period between
three and 10 months. This is itself followed by a period of
stabilized (almost constant) low risk of death, starting 10
months after therapy initiation. A 95% confidence region
is given in Figure 4, and is produced by varying vector a =
(a1, a2) around â = (3, 10) and considering the region
where  . The interpretation
is less straightforward than in the one-dimensional case.
Considering the two optimal values of the first and second
changepoints, the 95% confidence interval for the first
changepoint at a2 = 10 is between approximately one and
six months. The 95% confidence interval for the second
changepoint at a1 = 3 is approximately between three and
16.5 months. While not guaranteed by the construction of
the model, the confidence region, reassuringly, does not
include any points that would support a second change-
point that is temporally earlier than the first, i.e., there are
no points below the 45-degree diagonal.
Model comparison
Comparing the two best Weibull models with a one and
two changepoints via the Akaike Information Criterion
(AIC) and the Bayesian Information Criterion (BIC) (see
Methods section) produces AIC values of 1296.7 and
1293.3 for the one and two-changepoint models respec-
tively and BIC values of 1304.6 and 1303.9 respectively.
This means that the model with the two changepoints is
superior according to both the AIC and BIC.
−−≤= 25 9 9 29 5
2 [() () ] . ; LL aa χ
Survival estimates produced by Kaplan Meier versus a Weibull model with two changepoints (left panel) and hazard plot of the  Weibull two-changepoint model (right panel) Figure 3
Survival estimates produced by Kaplan Meier versus a Weibull model with two changepoints (left panel) and 
hazard plot of the Weibull two-changepoint model (right panel). This figure is similar to the one presented in Figure 
2 only the Weibull model with two changepoints (left panel) is now presented. The hazard plot of the Weibull two-change-
point model is also shown (right panel).
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Confidence region based on the inversion of the like-
lihood ratio test for the Weibull two-changepoint 
model. The straight line is the 45-degree diagonal. 
Any points below the diagonal would imply that a 
second changepoint is located earlier than the first 
changepoint. No such points were within the confi-
dence region. This figure shows the 95% confidence region 
for the two-changepoint model.
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Incorporating covariates
As an illustration of incorporating covariates into the
Weibull models with changepoints, we present the analy-
sis of the post-ART survival of male versus female patients.
There were 815 women in the data set (72.8% of the study
cohort) compared to 305 men. Maximizing the log profile
likelihood in (5), with gender as the covariate, adds β, the
associated survival regression coefficient, as an additional
parameter for maximization. Performing this analysis, the
optimal changepoint model is the one with two change-
points at a1 = 3 and a2 = 10 months post ART start. The
estimate of the Weibull regression coefficient is   =
0.411, which corresponds to a hazard ratio of 1.51 of
male compared to female patients.
Following the conditional variance estimation approach
in (6), we obtain var( ) = 0.0417. This in turn implies
that a 95% confidence interval of the hazard ratio will be
(1.01, 2.25). The Wald p value is p = 0.041 indicating an
increase in the hazard of mortality among men compared
to women. As it turned out in this application,
. However, this will not be
the case universally.  
The results from this analysis are shown pictorially in Fig-
ure 5. We should note that the model forced the change-
points to be at three and 10 months for both groups. We
also considered alternative analyses where the data for
men and women were fit separately and the optimal
changepoints were determined. There was no evidence to
suggest that the changepoints for men and women were
different.
Discussion
The main goal of this research is to establish, in a data-
driven manner, the existence, temporal location and
number of sharp changes in mortality risk (hazard of
death) after initiation of ART in a care and treatment pro-
gramme in sub-Saharan Africa. A number of investiga-
tions have reported that a high risk of death persists for
some time after ART initiation compared to later periods
[1-3]. Establishing the duration of this high risk period is
significant for refining clinical care protocols to better
manage these patients. For example, the frequency of
patient visits can be intensified for high-risk individuals
and patient counselling and outreach can also be consid-
ered over this crucial period.
The existence of a changepoint of risk has been empiri-
cally placed at some time during the first three to six
months of therapy by a number of reports. To my knowl-
edge however, there has never been an objective estimate
of its location generated by rigorous data analysis. In this
report I have attempted to use a data-driven approach, by
extending the Weibull model, to account for sharp
changes in the hazard of mortality. Using these extended
ˆ β
ˆ β
var( ) var[ |( , )] ββ ≈ {} Ea a 12
Survival estimates produced by Kaplan Meier versus a Weibull model with two changepoints for male and female patients Figure 5
Survival estimates produced by Kaplan Meier versus a Weibull model with two changepoints for male and 
female patients. The figure is similar to the one presented in the left panel of Figure 3 but includes a stratification by gender 
to illustrate the methodology when subject subgroups are considered.
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Weibull models allowed an objective estimation of the
possible location of changepoints in the risk of death of
HIV-infected patients after they initiate antiretroviral ther-
apy. These parametric models may be superior to semipar-
ametric models (such as the Cox proportional hazards
model) in this setting because they make explicit model-
ling of the underlying mortality risk (baseline hazard). As
cited in [4], from a quote attributed to Hjort [12], a "par-
ametric version [of the Cox model] ... if found to be ade-
quate, would lead to more precise estimation of survival
probabilities and ... concurrently contribute to a better
understanding of the phenomenon under study". Using
semiparametric models would have required a much
more complex modelling exercise, where factors associ-
ated with the changepoints would have to be included
among the model predictors.
These analyses show that an early changepoint is likely to
exist at about three months after initiation of ART. The
presence of this early changepoint is supported by a
number of reports. Stringer and colleagues [3], describing
the experience of the national antiretroviral therapy pro-
gramme in Zambia, report that 71% of all deaths in their
cohort happened during the first 90 days after initiation of
ART. Braitstein and colleagues [1], in a large study of
2,725 HIV-infected persons in 18 antiretroviral pro-
grammes in Africa, Asia and South America, report that
mortality rates were 14.7% and 10.6% in the first and sec-
ond month after ART initiation respectively but dropped
to 5.1% in months three to six, and then dropped further
to 2.7% in months 6–12. These results are similar to our
experience summarized in Table 1. The biological plausi-
bility of an initially very high hazard of mortality that rap-
idly declines over the first few months after initiation of
ART is supported by a number of factors. Since all patients
involved in this study were treatment-naïve, early drug
toxicity may have played a significant role in their ability
to adhere to the new medication regimens. In addition,
the rapid restoration of immune function immediately
after initiation of therapy, may have led to an inflamma-
tory response, what is called an Immune Reconstitution
Inflammatory Syndrome (IRIS) that can be fatal for the
patient. In a prospective study in South Africa, IRIS
occurred in 10% of the patients at a median time 48 days
after initiating ART [13], particularly among the most
immunosuppressed patients. A number of authors have
identified IRIS as having a significant burden in the con-
text of rapid immunological reconstitution in the pres-
ence of latent co-infections, particularly in the developing
world, where IRIS is "unmasking" a latent existing oppor-
tunistic infection or cancer. Given the burden of crypto-
coccosis deaths in the early period after ART initiation in
this study, fatal IRIS-related to inflammatory immune
response to this disease may have been present (see
Moore et al., 14th CROI presentation http://www.retro
conference.org/2007/Abstracts/28827.htm for more
information). A relevant case report of fatal cryptococco-
sis-related IRIS can be found in Seddon and colleagues
[14]. The most explicit attribution of early excess death to
IRIS is given in Celentano & Beyer [15] who cite a number
of investigators discussing fatal cases of IRIS in the context
of tuberculosis [16] and cryptococcal antigenemia [17].
The median CD4+ T cell count at ART start (analysis not
shown) was 128 cells/ml for this cohort with 25% of the
patients having CD4 counts half of that level, implying
significant immunosuppression. It has long been recog-
nized that CD4 counts below 200 cells/ml expose HIV-
infected patients to a very high risk for opportunistic
infections and death, the main reason why therapy is
started when CD4 count drops below that level. Given
that, on average, patients gain about 100 cells/ml in the
first six weeks of treatment and a further 60 cells/ml dur-
ing the subsequent months of the first year of antiviral
therapy [3,18], it is likely that the majority of subjects in
the present study reached CD4 counts above 200 cells/ml
only after the first three months of starting ART. Conse-
quently, co-infections and morbidities present at the start
of ART or acquired in the first months of therapy likely
continued to present a significant mortality risk during
this period.
We also showed that these generalized Weibull models
with changepoints can easily accommodate covariates. In
the example provided, men experienced considerably
higher mortality compared to women as implied by the
50% higher hazard of death. This has been consistently
reported in both the developed and developing world set-
ting [18,19]. In our context, men tend to be more immu-
nosuppressed than women when starting ART. This is
because of a number of issues that are beyond the scope
of this report. Men also exhibit higher levels of loss to fol-
low-up compared to women [18]. In our cohort, men had
lower median CD4 count at ART start than women (anal-
ysis not shown).
Despite higher mortality rates among HIV-infected men,
both men and women experience high mortality within
the first few months after starting ART. This observation in
turn implies that, along with gender, patient follow-up
and outreach efforts should be directed towards patients
that have recently been started on ART: see [20] for
description of such a tiered patient outreach protocol.
The existence of a period of moderate mortality risk even
past the three-month point, as suggested by the second
changepoint, is not surprising given the deep immuno-
suppression of this study cohort. Nevertheless, persistence
of risk up to the first year after starting ART has less clear
precedent in the literature, although the mortality rates
quoted in some of the aforementioned references suggestJournal of the International AIDS Society 2009, 12:9 http://www.jiasociety.org/content/12/1/9
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that mortality rates stabilize only after about one year
from initiation of ART. Evidence from our models is
equivocal on this issue. The AIC and BIC criteria applied
to the Weibull models with changepoints did favour the
model with two changepoints, but their values were close
and, as mentioned in Royston and Parmar [4], in the con-
text of a similar class of generalized Weibull models, they
should not be used mechanically in selecting the best
model. Thus, the evidence for a second changepoint of
mortality risk remains weak at present. Additional analy-
ses of similar data with longer follow-up are warranted to
elucidate this issue.
Extensions of the Weibull model have been considered by
a number of authors. Royston and Parmar [4] have pre-
sented a rich class of models that use cubic splines to
approximate s(x; γ) in (1) by adding higher-order polyno-
mial terms and one or more "knots" that add flexibility to
the shape of the survival curve not available in the simple
Weibull model. The methodology has been implemented
in [21] and [22] in the STATA software (that also includes
similar extensions to the log-logistic survival model).
Analysis of the data in this paper (not shown) using the
spline models produced virtually identical survival esti-
mates as those generated by the Weibull models with
changepoints. A significant advantage of the generalized
class of Weibull models of Royston and Parmar is that the
resulting hazard plot is continuous unlike the hazard
curves produced by the models considered in this work,
which have discontinuities at the changepoints. However,
the number and placement of the spline knots does not
have the same direct biological interpretation as the
number and location of changepoints. Thus, the general-
ized models with splines are less suitable in an effort to
estimate the number and location of possible abrupt
changes in patient survival, which was the primary goal of
this research.
Conclusion
The hazard of mortality is very high after ART initiation
for up to three months, and may persist up to a year after
start of treatment. This has strong implications for patient
management and may be helpful in refining patient care
protocols in this setting by intensifying follow-up of
newly treated patients during this period and possibly
extending the duration of intensified follow-up for up to
one year after start of therapy. Further investigation and
re-analysis of data from a number of ongoing studies will
be important to authoritatively address this question. The
flexibility afforded by these Weibull models will be useful
in this endeavor.
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